Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Friday, March 6, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.25 to $35,021,994.00.

Highlighted Stocks Traded by Insiders:

Hydrogenics (HYGS) - FREE Research Report

CommScope, Inc. of North Carolina, who is 10% Owner at Hydrogenics, sold 19,990 shares at $14.41 on March 6, 2015. Following this transaction, the 10% Owner owned 1.4 million shares meaning that the stake was reduced by 1.41% with the 19,990-share transaction.

The shares most recently traded at $14.91, up $0.50, or 3.34% since the insider transaction. Historical insider transactions for Hydrogenics go as follows:

  • 4-Week # shares sold: 71,324
  • 12-Week # shares sold: 124,756
  • 24-Week # shares sold: 206,756

The average volume for Hydrogenics has been 83,100 shares per day over the past 30 days. Hydrogenics has a market cap of $149.1 million and is part of the industrial goods sector and industrial industry. Shares are up 11.51% year-to-date as of the close of trading on Friday.

Hydrogenics Corporation, together with its subsidiaries, designs, develops, and manufactures hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. Currently, there are 2 analysts who rate Hydrogenics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HYGS - FREE

TheStreet Quant Ratings

rates Hydrogenics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Hydrogenics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Stanley Furniture (STLY) - FREE Research Report

Lapey John D., who is Director at Stanley Furniture, bought 7,600 shares at $3.25 on March 6, 2015. Following this transaction, the Director owned 370,326 shares meaning that the stake was boosted by 2.1% with the 7,600-share transaction.

The shares most recently traded at $3.49, up $0.24, or 6.89% since the insider transaction. Historical insider transactions for Stanley Furniture go as follows:

  • 4-Week # shares bought: 40,839
  • 4-Week # shares sold: 5,450
  • 12-Week # shares bought: 40,839
  • 12-Week # shares sold: 5,450
  • 24-Week # shares bought: 76,946
  • 24-Week # shares sold: 5,450

The average volume for Stanley Furniture has been 42,800 shares per day over the past 30 days. Stanley Furniture has a market cap of $50.7 million and is part of the consumer goods sector and consumer durables industry. Shares are up 25.18% year-to-date as of the close of trading on Friday.

Stanley Furniture Company, Inc. designs, manufactures, and imports wood furniture for the residential market in the United States. Currently, there are no analysts who rate Stanley Furniture a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on STLY - FREE

TheStreet Quant Ratings

rates Stanley Furniture as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, poor profit margins and feeble growth in the company's earnings per share. Get the full

Stanley Furniture Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IGI (IG) - FREE Research Report

Life Sciences Opportunities Fund Ii Lp, who is 10% Owner at IGI, sold 2.0 million shares at $9.95 on March 6, 2015. Following this transaction, the 10% Owner owned 8.4 million shares meaning that the stake was reduced by 19.31% with the 2.0 million-share transaction.

The shares most recently traded at $8.51, down $1.44, or 16.92% since the insider transaction. Historical insider transactions for IGI go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2.0 million
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 2.0 million
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 2.0 million

The average volume for IGI has been 1.1 million shares per day over the past 30 days. IGI has a market cap of $497.8 million and is part of the health care sector and drugs industry. Shares are up 7.16% year-to-date as of the close of trading on Friday.

IGI Laboratories, Inc. develops, manufactures, and markets topical formulations in the United States. The company sells its generic topical pharmaceutical products under the IGI label. Currently, there are 2 analysts who rate IGI a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IG - FREE

TheStreet Quant Ratings

rates IGI as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

IGI Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null